Check out the 2018 Health Influencer 50 from MM&M and its sister Haymarket Media brand, PRWeek. It includes profiles of the most influential names in healthcare, as well as in-depth features on how social media is bringing fresh voices into the marketing mix and the question of who influences the influencers.
Esperion Therapeutics said a combination of its once-a-day cholesterol treatment plus statin lowered LDL cholesterol by more than 18% compared to statins alone. It plans to file with the FDA early next year, setting up a face-off with existing, pricey PCSK9 drugs. (STAT)
Have we reached peak CBD? The non-hallucogenic component of cannabis is suddenly everywhere. Its proponents swear it can treat everything from inflammation to anxiety to PTSD, but skeptics say it’s essentially modern-day snake oil. (New York Times)
The Justice Department has reached a $25 million settlement with Abbott Laboratories and AbbVie over allegations that the two pharma companies gave kickbacks to doctors who prescribed their cholesterol drug for off-label uses. Neither company admitted wrongdoing. (Reuters)
Some cancer patients are being forced to choose between continuing expensive treatments that could extend their lives or stopping them so that their families aren’t left with a mountain of debt. Costly experimental treatments, such as precision medicine, in which a treatment plan is developed based on the genes in a patient’s tumors, can be very effective, but are almost never covered by private insurers. (USA Today)